Literature DB >> 3812521

The ethics of randomized clinical trials.

F Rosner.   

Abstract

Randomized clinical trials pose a number of fundamental ethical problems to which morally sensitive investigators must give careful consideration. The randomized double-blind clinical trial is ethically justified and the preferred method of demonstrating therapeutic effectiveness and safety. Alternate methods such as crossover and self-controlled designs, the use of historical controls, observational methods, and practitioner's clinical trials also exist and have their place in certain circumstances. The use of randomized double-blind clinical trials must assure adequate explanation of the research plan to the patient, the documentation of informed consent, adequate consideration of safety, and an acceptably low risk/benefit ratio.

Entities:  

Keywords:  Analytical Approach; Biomedical and Behavioral Research

Mesh:

Substances:

Year:  1987        PMID: 3812521     DOI: 10.1016/0002-9343(87)90069-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Knowledge of the Tuskegee study and its impact on the willingness to participate in medical research studies.

Authors:  V L Shavers; C F Lynch; L F Burmeister
Journal:  J Natl Med Assoc       Date:  2000-12       Impact factor: 1.798

2.  Randomized trials in oncology: a fertile ground for controversy.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

3.  Routinely collected data and comparative effectiveness evidence: promises and limitations.

Authors:  Lars G Hemkens; Despina G Contopoulos-Ioannidis; John P A Ioannidis
Journal:  CMAJ       Date:  2016-02-16       Impact factor: 8.262

Review 4.  Ethical considerations in neuroclinical trials.

Authors:  S N Macciocchi; W A Alves
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

5.  Can "ethical" clinical trials be unethical?

Authors:  M Kaye
Journal:  CMAJ       Date:  1987-12-01       Impact factor: 8.262

6.  Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol.

Authors:  J A Korvick; J E Peacock; R R Muder; R R Wheeler; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

7.  Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.

Authors:  Nelson B Watts; Robert Lindsay; Zhengqing Li; Chandrasekhar Kasibhatla; Jacques Brown
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

8.  Participation of pharmacists in clinical trial recruitment for low back pain.

Authors:  Christina Abdel Shaheed; Christopher G Maher; Kylie A Williams; Andrew J McLachlan
Journal:  Int J Clin Pharm       Date:  2014-08-08

Review 9.  Is it ethical to use placebos in osteoporosis clinical trials?

Authors:  Nelson B Watts
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

10.  SMART designs in cancer research: Past, present, and future.

Authors:  Kelley M Kidwell
Journal:  Clin Trials       Date:  2014-04-14       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.